Worth reading
35Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
6609
¥ million (year-on-year increase in revenue)Wording
Definitive
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportFirst quarter of the fiscal year ending March 20274 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales49,704 million yen+15.3%
Operating profit7,881 million yen+2.1%
Ordinary income9,753 million yen+57.8%
Net income6,457 million yen+47.8%
Gross Profit Margin45.5 %
Operating profit margin15.9 %
Selling, general and administrative expenses14,715 million yen
Results for the three months of the current quarter
Net Sales
49,704 million yen
Operating profit
7,881 million yen
Ordinary income
9,753 million yen
Net income
6,457 million yen
Full-year earnings forecast
Net Sales
213,600 million yen
Operating profit
37,500 million yen
Ordinary income
35,500 million yen
Net income
26,200 million yen
What the company explained in this material
Key KPIsA metric the company considers important as a management benchmark.
- Sales of 129 prescription pharmaceutical formulations39,759 million yenYear-on-year (%)6.8
- Sales of existing-drug development formulations10,492 million yenYear-on-year (%)6.2
- Sales of Growing formulations6,734 million yenYear-on-year (%)12
- Value-based growth rate for 129 prescription pharmaceutical formulations6.8 %
- Volume-based growth rate for 129 prescription pharmaceutical formulations6.9 %
- Number of formulations with value growth87 formulationsYear on year against the same period last year+61.0%
Segment results
- Domestic BusinessNet Sales41,475 million yenYear-on-Year Change in Revenue (%)6.7Operating profit7,498 million yenOperating profit year-on-year_pct-6
- China OperationsNet Sales8,228 million yenYear-on-Year Change in Revenue (%)94.8Operating profit382 million yenOperating profit year-on-year_pct336.8
Number of employees
Number of Employees4,958 people
Prior-year period4,312 people
Capital expenditures
2,967 million yen
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | First quarter of the fiscal year ending March 2027 |
| Net Sales | 49,704 million yen (YoY +15.3%) |
| Operating profit | 7,881 million yen (YoY +2.1%) |
| Ordinary income | 9,753 million yen (YoY +57.8%) |
| Net income | 6,457 million yen (YoY +47.8%) |
| Gross Profit Margin | 45.5 % |
| Operating profit margin | 15.9 % |
| Selling, general and administrative expenses | 14,715 million yen |
| Results for the three months of the current quarter | Net Sales 49,704 million yen / Operating profit 7,881 million yen / Ordinary income 9,753 million yen / Net income 6,457 million yen |
| Full-year earnings forecast | Net Sales 213,600 million yen / Operating profit 37,500 million yen / Ordinary income 35,500 million yen / Net income 26,200 million yen |
| Segment results | Segment Domestic Business / Net Sales 41,475 million yen / Year-on-Year Change in Revenue (%) 6.7 / Operating profit 7,498 million yen / Operating profit year-on-year_pct -6, Segment China Operations / Net Sales 8,228 million yen / Year-on-Year Change in Revenue (%) 94.8 / Operating profit 382 million yen / Operating profit year-on-year_pct 336.8 |
| Key KPIs | Indicator name Sales of 129 prescription pharmaceutical formulations / Value 39,759 million yen / Year-on-year (%) 6.8 million yen, Indicator name Sales of existing-drug development formulations / Value 10,492 million yen / Year-on-year (%) 6.2 million yen, Indicator name Sales of Growing formulations / Value 6,734 million yen / Year-on-year (%) 12 million yen, Indicator name Value-based growth rate for 129 prescription pharmaceutical formulations / Value 6.8 % / Year on year against the same period last year Not disclosed, Indicator name Volume-based growth rate for 129 prescription pharmaceutical formulations / Value 6.9 % / Year on year against the same period last year Not disclosed, Indicator name Number of formulations with value growth / Value 87 formulations / Year on year against the same period last year 61 formulations |
| Number of employees | Number of Employees 4,958 people / Prior-year period 4,312 people |
| Capital expenditures | 2,967 million yen |
Items this document does not state (16)
Progress against full-year forecastSelf-assessment against the planBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&ANew initiatives
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company has not provided a written explanation for the reasons behind the changes in performance.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.